Treatment of Mycobacterium intracellulare Infection
Treat Mycobacterium intracellulare pulmonary disease with a macrolide-based three-drug regimen consisting of clarithromycin (1,000 mg) or azithromycin (500 mg), rifampin (600 mg), and ethambutol (25 mg/kg) given three times weekly for nodular/bronchiectatic disease, or daily for cavitary/severe disease, continuing for at least 12 months after sputum culture conversion 1.
Treatment Algorithm by Disease Severity
For Nodular/Bronchiectatic Disease (Non-cavitary)
- Clarithromycin 1,000 mg OR Azithromycin 500 mg (three times weekly)
- Rifampin 600 mg (three times weekly)
- Ethambutol 25 mg/kg (three times weekly)
This intermittent regimen achieves similar sputum conversion rates as daily therapy while being better tolerated and critically, does not lead to macrolide resistance development 2.
For Cavitary or Severe/Advanced Disease
- Clarithromycin 500-1,000 mg OR Azithromycin 250 mg (daily)
- Rifampin 600 mg OR Rifabutin 150-300 mg (daily)
- Ethambutol 15 mg/kg (daily)
- Consider adding Amikacin or Streptomycin three times weekly for the initial 2-3 months 1
The daily regimen is necessary for cavitary disease as there is insufficient evidence supporting intermittent therapy for this presentation 2.
Duration of Therapy
Continue treatment until sputum cultures remain negative for at least 12 months 1. The median time from culture conversion to treatment completion in successful cases is approximately 7 months (221.5 days) 3.
Critical Treatment Principles
Preventing macrolide resistance is the highest priority. M. intracellulare (part of MAC) requires a three-drug regimen rather than two drugs because insufficient data exist to determine macrolide resistance risk with dual therapy 2. Ethambutol specifically prevents macrolide resistance development and must not be omitted 4.
Monitoring Treatment Response
- Positive sputum smears after 6 months of treatment predict treatment failure (microbiological cure rate drops from 44% to 6%) 3
- Patients achieving culture conversion have approximately 87-100% microbiological cure rates 3, 5
- The 1-year relapse rate after successful treatment is 17%, often due to reinfection rather than true relapse 3, 4
Drug Susceptibility Testing
Perform susceptibility testing for clarithromycin only as routine testing for M. intracellulare 1. Clarithromycin resistance significantly worsens prognosis and requires alternative regimens 4. Recent data shows M. intracellulare has high susceptibility to moxifloxacin (95.9%), amikacin (90.1%), clarithromycin (91.7%), and rifabutin (90.1%) 6.
Alternative Regimens
For Rifampin Intolerance or Severe Disease
Substitute clofazimine 100 mg daily for rifampin. This regimen (macrolide + ethambutol + clofazimine) achieved 87% sputum conversion with 67% overall success in one study, though 19% relapsed after treatment completion 5.
For Refractory or Macrolide-Resistant Disease
- Add amikacin (inhaled or parenteral)
- Consider clofazimine, bedaquiline, or moxifloxacin as adjunctive agents 7, 4
- Surgical resection for localized disease achieves approximately 93% sputum conversion rates in appropriate candidates 4
Common Pitfalls
- Do not use two-drug regimens (macrolide + ethambutol alone) due to macrolide resistance concerns 2
- Do not use intermittent therapy for cavitary disease—daily dosing is required 2
- Do not stop treatment before 12 months of culture negativity—shorter courses increase relapse risk 1
- Do not omit ethambutol—it prevents macrolide resistance even when in vitro susceptibility suggests otherwise 4
Special Populations
HIV/AIDS Patients with Disseminated Disease
Use clarithromycin 1,000 mg/day OR azithromycin 250 mg/day plus ethambutol 15 mg/kg/day with or without rifabutin 150-350 mg/day. Continue until symptom resolution and immune reconstitution occurs 1, 8. Address drug interactions between rifamycins and antiretroviral protease inhibitors—consider substituting a macrolide or moxifloxacin for the rifamycin if necessary 1, 8.